Edgar Filing: GALECTIN THERAPEUTICS INC - Form 4

GALECTIN Form 4 January 14,	THERAPEUTIC	CS INC										
FORN Check th if no lon subject to Section Form 4 Form 5 obligation may corn <i>See</i> Insta 1(b).	A 4 UNITED his box liger to 16. or Filed pur Section 17(MENT OF rsuant to S (a) of the F	Wa F CHAN Section 1 Public U	Ishingtor NGES IN SECU I6(a) of t Utility Ho	n, D.C. 20 N BENEF RITIES he Securi	ICIA ties E	L OWN Exchange y Act of 1	OMMISSION ERSHIP OF Act of 1934, 1935 or Section	OMB AP OMB Number: Expires: Estimated a burden hour response			
(Print or Type	Responses)											
1. Name and a 10X Fund,	Person <u>*</u>						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) 1099 FOREST LAKE TERRACE			3. Date of Earliest Transaction (Month/Dav/Year)					Director Officer (give title Other (specify below) below)				
NICEVILL		Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative	Secu	ities Acqu	ired, Disposed of,	or Beneficiall	y Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	ed 3. 4. Securities Acquired (A Date, if Transaction Disposed of (D) Code (Instr. 3, 4 and 5) ay/Year) (Instr. 8) (A)				D)	Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V		or (D)	Price \$	(Instr. 3 and 4)				
Common Stock	01/10/2014			S	42,000 (1)	D	16.0028 (2)	9,415,422 <u>(3)</u>	D			
Common Stock	01/13/2014			S	58,000 (1)	D	\$ 14.0035 (4)	9,357,422 <u>(3)</u>	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: GALECTIN THERAPEUTICS INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address Director 10% Owner Officer Other									
Director 10% Owner Officer Other									
10X Fund, L.P.1099 FOREST LAKE TERRACEXNICEVILLE, FL 32578									
10X Capital Management, LLC1099 FOREST LAKE TERRACENICEVILLE, FL 32578									
Signatures									
/s/ James C. Czirr, as Managing Member of the General Partner for 10X Fund, LP									
**Signature of Reporting Person	Date								

/s/ James C. Czirr, as Managing Member of 10X Capital Management, LLC
<u>**</u>Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Issuer is aware of potential short-swing liability issues related to the transaction reported herein and a transaction reported by the(1) Issuer's Executive Chairman that occurred on November 15, 2013. The issuer is taking steps to collect any short-swing profit created by such transactions.

Reflects weighted average price. Range of prices were between \$15.68 and \$16.35. The reporting person will provide upon request by the(2) Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

(3) 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims

01/14/2014

Date

Edgar Filing: GALECTIN THERAPEUTICS INC - Form 4

beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

Reflects weighted average price. Range of prices were between \$13.65 and \$14.23. The reporting person will provide upon request by the

(4) Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.